💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tofacitinib Citrate

CHEMBL2103743 Phase 4 Approuvé Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
504.5 g/mol
LogP
—
Phase
4

A citrate salt form of tofacitinib with the same therapeutic properties. This oral JAK inhibitor is used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and atopic dermatitis in patients who have not responded adequately to other treatments.

Masse moléculaire

504,5000 g/mol

TPSA

221,00 Ų

Aires thérapeutiques

Age-Related Macular Degeneration Respiratory Disease Pain Management Rheumatoid Arthritis Migraine Generalized Anxiety Disorder Inflammatory Bowel Disease Psoriasis Systemic Lupus Erythematosus Lymphoma Transplant Medicine Atopic Dermatitis Chronic Pain

Mécanisme d'action

Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C16H20N6O.C6H8O7/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t11-,13+;/m1./s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H28N6O8

                    

                    
                    

                        
HBD / HBA

                        
5 / 12

                    

                    
                    

                        
Liaisons Rotatives

                        
8

                    

                    
                    
                    

                        
Atomes Lourds

                        
36

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
A citrate salt form of tofacitinib with the same therapeutic properties. This oral JAK inhibitor is used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and atopic dermatitis in patients who have not responded adequately to other treatments.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Tofacitinib Citrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2103743.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 10174505.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.